ONCO Stock Analysis: Buy, Sell, or Hold?
ONCO - Onconetix, Inc. Common Stock
$0.32
-0.06 (-15.53%)
▼
5d:
-21.44%
30d:
-57.31%
90d:
-59.75%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: Jun 11, 2026
23d
Get Alerted When ONCO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
11 traders called ONCO this week
74% bullish • 6 bearish
74% bullish • 6 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ONCO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ONCO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ONCO is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.46 to $1.03.
Technical Outlook: Technically, ONCO is in a downtrend. The price is currently testing key support at $0.33. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.5% recently.
Market Sentiment: ONCO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.00 (+2306.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ONCO is in a downtrend. The price is currently testing key support at $0.33. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.5% recently.
Market Sentiment: ONCO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.00 (+2306.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.46 -
$1.03
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-15.5%)
- BULLISH: Trading 2306.4% below Wall St target ($9.00)
- CAUTION: 5-day price weakness (-21.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.46 -
$1.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.33
Resistance Level
$0.58
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Wall Street Target
$9.00
(+2306.4%)
Revenue Growth (YoY)
-78.9%
Share & Embed Analysis
Last updated: May 18, 2026 3:00 PM ET
Data refreshes hourly during market hours. Next update: 4:00 PM
Data refreshes hourly during market hours. Next update: 4:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONCO showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
NEUTRAL
Recent Transactions
Financial Lp Hrt
SELL
49710 shares
2026-04-21
Financial Lp Hrt
SELL
94462 shares
2026-04-20
Financial Lp Hrt
BUY
34636 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 53 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 58 HOLD |
